亚沙林因通过激活PPARγ,减轻了白血素诱导的肺纤维化
Qian Zeng1, Ting-Ting Zhou1, Wen-Jie Huang2
1Xiangya Nursing School, Central South University, 172 Tongzipo Road, Changsha, 410013, Hunan, China.
Scientific reports
|September 7, 2023
概括
一种天然化合物阿萨里宁通过激活PPARγ有效治疗肺纤维化. 这项研究强调了阿萨里宁作为这种渐进性肺病的有前途的治疗剂.
科学领域:
- 药理学 药理学是指药理学的学科.
- 肺部病理学 肺部病理学
- 自然产品 自然产品
背景情况:
- 异形性肺纤维化 (IPF) 是一种严重的肺病,治疗选择有限,预后不佳.
- 过氧体增殖器激活受体玛 (PPARγ) 是肺纤维化的一种已知的治疗点.
- 阿萨里宁是来自Asarum heterotropoides的一种基,具有潜在的治疗性质.
研究的目的:
- 为了研究阿萨里宁在白素诱导的肺纤维化小鼠模型上的治疗效果.
- 阐明阿萨里宁作用的基本机制,特别是与PPARγ的相互作用.
主要方法:
- 在小鼠中建立一个肺纤维化模型,使用白素.
- 使用阿萨里宁和PPARγ抑制剂GW9662.
- 在体外研究TGF-β1诱导的纤维细胞转变为肌纤维细胞.
- 对Smad,AKT和MAPK信号通路的分析.
主要成果:
- 在小鼠中,阿沙林因显著减轻了肺纤维化.
- 阿萨里宁的治疗效果被PPARγ抑制剂GW9662.2.减弱.
- 亚沙林在体外抑制了纤维细胞向肌纤维细胞的过渡,这种效应被GW9662和PPARγ基因沉默所阻碍.
- 亚沙林因通过PPARγ激活调节了TGF-β信号通路,包括Smad,AKT和MAPK.
结论:
- 阿沙林因在肺纤维化中显示出显著的治疗潜力.
- PPARγ被确定为关键的分子标,调解阿萨林的抗纤维效应.
- 阿萨里宁代表了一种有前途的天然化合物,可用于开发新的IPF治疗方法.
相关概念视频
01:18Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
197
Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
197
01:23Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
210
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
210
01:26Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
199
Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
199